vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Laird Superfood, Inc. (LSF). Click either name above to swap in a different company.
Laird Superfood, Inc. is the larger business by last-quarter revenue ($13.3M vs $10.7M, roughly 1.2× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -13.2%, a 36.7% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 15.0%). Over the past eight quarters, Laird Superfood, Inc.'s revenue compounded faster (16.1% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
ABUS vs LSF — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $13.3M |
| Net Profit | $2.5M | $-1.8M |
| Gross Margin | — | 34.1% |
| Operating Margin | 13.9% | -13.5% |
| Net Margin | 23.5% | -13.2% |
| Revenue YoY | 522.2% | 15.0% |
| Net Profit YoY | 112.7% | -341.4% |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.3M | ||
| Q3 25 | — | $12.9M | ||
| Q2 25 | $10.7M | $12.0M | ||
| Q1 25 | — | $11.7M | ||
| Q4 24 | — | $11.6M | ||
| Q3 24 | — | $11.8M | ||
| Q2 24 | — | $10.0M | ||
| Q1 24 | — | $9.9M |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-975.1K | ||
| Q2 25 | $2.5M | $-362.2K | ||
| Q1 25 | — | $-156.2K | ||
| Q4 24 | — | $-398.4K | ||
| Q3 24 | — | $-166.1K | ||
| Q2 24 | — | $-239.1K | ||
| Q1 24 | — | $-1.0M |
| Q4 25 | — | 34.1% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | 39.9% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 43.0% | ||
| Q2 24 | — | 41.8% | ||
| Q1 24 | — | 40.0% |
| Q4 25 | — | -13.5% | ||
| Q3 25 | — | -7.7% | ||
| Q2 25 | 13.9% | -3.3% | ||
| Q1 25 | — | -1.9% | ||
| Q4 24 | — | -4.1% | ||
| Q3 24 | — | -2.3% | ||
| Q2 24 | — | -3.4% | ||
| Q1 24 | — | -11.0% |
| Q4 25 | — | -13.2% | ||
| Q3 25 | — | -7.6% | ||
| Q2 25 | 23.5% | -3.0% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | -3.4% | ||
| Q3 24 | — | -1.4% | ||
| Q2 24 | — | -2.4% | ||
| Q1 24 | — | -10.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0.01 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $5.1M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $11.5M |
| Total Assets | $103.3M | $19.2M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.1M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | $37.4M | $3.9M | ||
| Q1 25 | — | $7.0M | ||
| Q4 24 | — | $8.3M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | — | $7.6M | ||
| Q1 24 | — | $7.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $11.5M | ||
| Q3 25 | — | $12.8M | ||
| Q2 25 | $83.0M | $13.4M | ||
| Q1 25 | — | $13.3M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | — | $13.1M | ||
| Q2 24 | — | $12.6M | ||
| Q1 24 | — | $12.7M |
| Q4 25 | — | $19.2M | ||
| Q3 25 | — | $18.9M | ||
| Q2 25 | $103.3M | $20.4M | ||
| Q1 25 | — | $21.5M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | $18.8M | ||
| Q2 24 | — | $18.0M | ||
| Q1 24 | — | $17.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $68.4K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $68.4K | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | $-15.7M | $-2.8M | ||
| Q1 25 | — | $-1.3M | ||
| Q4 24 | — | $339.2K | ||
| Q3 24 | — | $305.8K | ||
| Q2 24 | — | $642.7K | ||
| Q1 24 | — | $-422.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
